Following a similar decision in case the trade group Outsourcing Facilities Association brought against FDA over its decision ...

Tirzepatide linked to more GI issues than semaglutide in new study on weight-loss drugs without diabetes. Read more!

Disparities in prescribing semaglutide and tirzepatide for obesity reveal social factors affecting access and highlight the ...

Tirzepatide was associated with better glycemic control and weight loss outcomes than semaglutide and insulin among patients with T2D.

Semaglutide has been shown to reduce the risk of complications in patients with chronic kidney disease, an indication for which it has been filed for approval, while tirzepatide has been shown to ...

Semaglutide and tirzepatide aid weight loss by mimicking gut hormones Ozempic, Wegovy, Mounjaro and Zepbound treat diabetes, support weight loss The weight loss drugs differ in FDA-approved uses ...

Sharp increases were seen in dispensations of tirzepatide (0.0 to 40.6%) and semaglutide (2.4 mg; 0.0 to 32.2%) among adults without diabetes but prescribed WLMs; the most frequently dispensed WLM ...

Between 2021 and 2023, prescriptions of tirzepatide, semaglutide (Novo Nordisk), and sodium-glucose cotransporter 2 (SGLT2) inhibitors for people with T2D increased dramatically, while the use of ...

Semaglutide 2.0 mg was the most initiated medication (34.0%) vs 16.1% who initiated tirzepatide. Any use of tirzepatide jumped to 12.3% of all GLM use by December 2023, while SGLT2 inhibitor and ...

Compounded drugs are custom-made and unbranded medications that contain the same active ingredient as a marketed drug, such as semaglutide or tirzepatide, pursuant to a prescription. A shortage of ...